Skip to content

Metformin in Pregnant PCOS Women

Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00159536
Acronym
PregMet
Enrollment
257
Registered
2005-09-12
Start date
2005-02-28
Completion date
2009-10-31
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

PCOS, metformin, pregnancy, preeclampsia, diabetes, preterm delivery

Brief summary

To investigate the effect of metformin on pregnancy complications and pregnancy outcome in the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.

Interventions

DRUGMetformin

Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study

DRUGPlacebo

Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study

Sponsors

St. Olavs Hospital
CollaboratorOTHER
Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* 18-45 years, * PCOS diagnosis according to Rotterdam criteria * single, viable, ultrasound verified fetus * if metformin was used at conception and early pregnancy, at least 7 days of wash out

Exclusion criteria

* known liver disease or ALAT \> 90 nmol/L * known renal disease or creatinine \> 110 micromol/L * diabetes mellitus * alcohol or drug abuse * peroral steroid treatment * cimetidine, anticoagulant or erythromycin treatment at time of inclusion * not suitable for other reasons

Design outcomes

Primary

MeasureTime frame
Gestational diabetesup to delivery
incidence of metabolic syndrome and neurophysiologic parameters in offspringWithin 18 years
Preterm deliveryup to delivery
pre-eclampsiaup to delivery

Secondary

MeasureTime frame
Incident of instrumental deliveriesat delivery
emesis and hyperemesisup to delivery
Snoring and sleep qualityup to delivery
Hormone levels in mother and offspringup to delivery
BreastfeedingOne year post partum
weight changeup to delivery
blood pressure changeup to delivery

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026